News

Article

Selinexor Receives Approval in South Korea for Multiple Myeloma

Fact checked by:

Key Takeaways

  • Selinexor, combined with bortezomib and dexamethasone, is approved in South Korea for multiple myeloma after one prior therapy.
  • The BOSTON trial showed SVd significantly improved progression-free survival and response rates over bortezomib and dexamethasone alone.
SHOW MORE

The South Korean Ministry of Food and Drug Safety approved selinexor plus bortezomib and dexamethasone for pretreated patients with multiple myeloma.

Multiple Myeloma - stock.adobe.com

Multiple Myeloma - stock.adobe.com

The South Korean Ministry of Food and Drug Safety has approved a supplemental new drug application (sBLA) for selinexor (Xpovio) in combination with bortezomib (Velcade) and dexamethasone (SVd) for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy.1

The announcement was made on the heels of 2 prior approvals in South Korea, listing selinexor for use in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma and as monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

On July 24, 2024, selinexor was added to the reimbursement drug list in South Korea, becoming the first XPO1 inhibitor to receive approval for public insurance coverage in the country. The agent is also included in national health insurance or reimbursement schemes in Australia and Singapore. 

In December 2020 the FDA approved SVd for the treatment of patients with multiple myeloma who have received at least 1 prior line of therapy. The approval was based on data from the phase 3 BOSTON trial (NCT03110562) which compared the regimen with bortezomib and dexamethasone (Vd) alone in patients who had received at least 1 but no more than 3 prior lines of therapy.2

At the time of approval, the study had demonstrated a statistically significant improvement in the primary end point of progression-free survival (PFS), showcasing an estimated PFS of 13.9 months (95% CI, 11.7-not estimable) with the investigational regimen vs 9.5 months (95% CI, 7.6-10.8) with Vd alone (HR, 0.70; 95% CI, 0.53-0.93; one-sided P = .0075). Additionally, the overall response rates with SVd and Vd were 76.4% (95% CI, 69.8%-82.2%) and 62.3% (95% CI, 55.3%-68.9%), respectively (one-sided P =.0012).3 With median follow-up of 17.4 months the median overall survival (OS) was not reached (NR) with SVd vs 25.0 months with Vd alone (HR, 0.84; 95% CI, 0.57-1.23; P =.19).4

Findings from an extended, post-hoc follow-up analysis recently published in the European Journal of Hematology demonstrated that at a median follow-up of over 28 months SVd maintained clinically meaningful improvements in PFS vs Vd alone across all subgroups. The median PFS in patients with lenalidomide (Revlimid)-refractory disease was 10.2 months with SVd vs 7.1 months with Vd (HR, 0.52; 95% CI, 0.31-0.88; P =.006). Patients who had not received a prior proteasome inhibitor had a median PFS of 29.5 months with SVd vs 9.7 months with Vd (HR, 0.29; 95% CI, 0.14-0.63; P <.001). Among those who were bortezomib-naïve the median PFS with SVd and Vd were 29.5 months and 9.7 months, respectively (HR, 0.35; 95% CI, 0.18-0.68; P =.001). Notably, patients who had received 1 prior line of therapy had an approximate doubling in median PFS with SVd, at 21.0 months vs 10.7 months with Vd alone (HR, 0.62; 95% CI, 0.41-0.95; P =.014).5

Patients with lenalidomide-refractory disease also experienced longer median OS with SVd, at 26.7 months vs 18.6 months with Vd alone (HR, 0.53; 95% CI, 0.30-0.95; P =.015). Patients who were proteasome inhibitor–naive and bortezomib-naive had a median OS that was NR in either arm (HR, 0.54; 95% CI, 0.25-1.20; P=.062 and HR, 0.56; 95% CI, 0.27-1.15; P =.055, respectively). Patients who had received 1 prior line of therapy experienced a median OS that was NR with SVd vs 32.8 months with Vd (HR, 0.91; 95% CI, 0.57-1.45; P =.344).5

Antengene, codeveloper of selinexor, has also submitted a new drug application for the agent in Indonesia, with approval expected in the second half of 2024.1

References

  1. Antengene announces Xpovio (selinexor) approved for its third indication in South Korea, bringing fresh hope to patients with MM in the country. News release. Antengene Corporation Limited. October 18, 2024. Accessed October 18, 2024. https://www.antengene.com/newsinfo/411
  2. FDA approves selinexor for refractory or relapsed multiple myeloma. FDA. December 18, 2020. Accessed October 18, 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selinexor-refractory-or-relapsed-multiple-myeloma#:~:text=On%20December%2018%2C%202020%2C%20the,at%20least%20one%20prior%20therapy
  3. Xpovio. Prescribing information. Karyopharm Therapeutics; 2020. Accessed October 18, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212306s005lbl.pdf
  4. Dimopoulos MA, Delimpasi S, Simonova M, et al. Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: initial results of the phase III BOSTON study. J Clin Oncol. 2020;38(suppl 5):8501. doi:10.1200/JCO.2020.38.15_suppl.8501
  5. Mateos MV, Engelhardt M, Leleu X, et al. Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: extended follow-up subgroup analysis of the BOSTON trial. Eur J Haematol. 2024;113(2):242-252. doi:10.1111/ejh.14223
Related Videos
Ajay K. Nooka, MD, MPH, FACP
Meletios A. Dimopoulos, MD
Binod Dhakal, MD
In this final episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil, discuss plans for developing guidelines and policies to enhance management of bispecific T-cell engagers across various centers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss the need for continued evaluation of prophylactic treatments like tocilizumab (Actemra) and antimicrobial measures for bispecific T-cell engagers, noting logistical and financial challenges and the importance of collaboration with community centers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil emphasize the need for comprehensive patient education, effective communication, and specific safety protocols to manage patients receiving bispecific T-cell engagers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss the challenges and strategies in managing bispecific T-cell engagers in the realm of cancer, emphasizing the importance of community and tertiary care collaboration to handle unique toxicities like cytokine release syndrome (CRS) and the need for well-defined protocols to ensure patient safety and effective treatment.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss bispecific T-cell engagers, highlighting their effectiveness in treating hematologic malignancies like multiple myeloma, their potential use in solid tumors, and the importance of managing unique adverse effects, such as cytokine release syndrome and infection risks.
Jill Corre, PharmD, PhD
Jill Corre, PharmD, PhD